search
Back to results

Theranostic Guided Riboflavin/UV-A Corneal Cross-linking (ARGO)

Primary Purpose

Keratoconus

Status
Active
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Riboflavin/UV-A corneal cross-linking
Sponsored by
Regensight
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Keratoconus focused on measuring theranostics, riboflavin, UV-A light, corneal cross-linking

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

criteria for inclusion in the clinical trial are those currently referred to as the golden standard for the treatment of corneal cross-linking. The criterion to determine progression of keratoconus is based on providing at least one of the following evidences:

  • at least two Placido disk corneal topography measurements showing at least +1.00 D steepening of the Kmax value in the last year or longer interval period.
  • at least two manifest refraction measurements showing at least -0.50 D change in spherical equivalent refraction in the last year or longer interval period.
  • at least two central corneal thickness (CCT) measurements showing at least -10 µm change in in the last year or longer interval period.

Exclusion Criteria:

  • Anterior corneal curvature steeper than 63 D;
  • Corneal thickness thinner than 400 µm;
  • Corneal scarring;
  • Descemetocele;
  • History of herpetic keratitis;
  • Concomitant eye diseases;
  • Inflammatory eye diseases;
  • Glaucoma;
  • Cataract;
  • Nistagmus;
  • Pregnancy;
  • Breast feeding.

Sites / Locations

  • Azienda Ospedaliera Universitaria Mater Domini - Università Magna Graecia di Catanzaro
  • Azienda Ospedaliera Universitaria Careggi, Università di Firenze
  • Azienda Ospedaliera Universitaria Policlinico G. Martino, Università di Messina

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Riboflavin/UV-A corneal cross-linking monitored by theranostic software module

Arm Description

One study arm receiving riboflavin/UV-A corneal cross-linking with either standard, Epi-OFF, or transepithelial, Epi-ON, treatment protocol. Only one eye of each participant is designated as the study eye.

Outcomes

Primary Outcome Measures

Validation of the theranostic score
The aim of this study is to validate the Theranostic Imaging Biomarker for theranostic-guided corneal corneal cross-linking (CXL) in patients with keratoconus

Secondary Outcome Measures

Corneal topography
Change of Maximum Simulated Keratometry
Endothelial Cell Density
Change of Endothelial Cell Density

Full Information

First Posted
July 11, 2022
Last Updated
January 31, 2023
Sponsor
Regensight
search

1. Study Identification

Unique Protocol Identification Number
NCT05457647
Brief Title
Theranostic Guided Riboflavin/UV-A Corneal Cross-linking
Acronym
ARGO
Official Title
Assessment of Theranostic Guided Riboflavin/UV-A Corneal Cross-linking for Treatment of Keratoconus
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 27, 2022 (Actual)
Primary Completion Date
January 31, 2024 (Anticipated)
Study Completion Date
January 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Regensight

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a clinical study consisting of a study arm to assess the performance of the theranostic software module (Research Use Only) of a CE marked (CE1936) UV-A medical device, C4V CHROMO4VIS™, in order to validate its use for theranostic-guided corneal cross-linking treatment of keratoconus and corneal ectasia. The study hypothesis is that theranostic-guided riboflavin/UV-A corneal cross-linking with the C4V CHROMO4VIS™ system is safe and can estimate treatment efficacy during operation, regardless of treatment protocol, i.e., either with or without epithelial removal.
Detailed Description
Keratoconus is a naturally-occurring ocular condition characterized by progressive thinning and steepening of the central cornea, resulting in corneal optical irregularities with increasing myopia, irregular astigmatism, corneal opacity and consequential loss of visual acuity. Riboflavin/UV-A corneal cross-linking is a procedure used to biomechanically stabilize the weak cornea in keratoconus and to slow down or halt the clinical progression of this disease. Theranostics is an emerging therapeutic paradigm that enables monitoring of image-guided therapy in clinic through the use of a theranostic module that makes use of real-time non-invasive molecular analysis of the tissue being treated to achieve optimal treatment outcomes in the management of disease. The theranostic software module of the C4V CHROMO4VIS™ medical device is able to measure the concentration of riboflavin into the cornea during treatment and to provide the surgeon with an objective assessment of treatment efficacy. The scope of this study is to validate the theranostic imaging biomarker score by assessing the change of corneal topography Kmax value at 1-year postoperatively. The 1-year follow-up is long enough to provide scientific evidence of the safety and efficacy of the theranostic UV-A medical device in question. A pre-operative examination will ensure that every interested and willing participant fulfils the inclusion criteria of this study. Post-operative examinations will be carried out after 1 week, 1 month, 3 months, 6 months and 12 months. This is a multi-center clinical trial. Eligible participants will be stratified with allocation ratio 1:1 into either treatment protocol (EpiOn and EpiOFF Thera-CXL) using a computer-generated stratification plan with blocks. Two different blocks are created, which include eyes with Kmax steeper or flatter than 54.0 D to allocate patients with comparable baseline Kmax values in either treatment protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Keratoconus
Keywords
theranostics, riboflavin, UV-A light, corneal cross-linking

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
One study arm receiving riboflavin/UV-A corneal cross-linking with either standard, Epi-OFF, or transepithelial, Epi-ON, treatment protocol. Only one eye of each participant is designated as the study eye.
Masking
None (Open Label)
Masking Description
Participant receives stratification to either corneal cross-linking protocol after consent form signature. Outcome assessor is masked. All participants wear contact lens after treatment until first postoperative eye examination at 1 week.
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Riboflavin/UV-A corneal cross-linking monitored by theranostic software module
Arm Type
Experimental
Arm Description
One study arm receiving riboflavin/UV-A corneal cross-linking with either standard, Epi-OFF, or transepithelial, Epi-ON, treatment protocol. Only one eye of each participant is designated as the study eye.
Intervention Type
Device
Intervention Name(s)
Riboflavin/UV-A corneal cross-linking
Intervention Description
Corneal cross-linking procedure will be performed using the theranostic software module of the C4V CHROMO4VIS™ system in all participants. Participants will receive a single dose of the 0.22% riboflavin ophthalmic solution, RitSight™. Application of the riboflavin eye drop will be done for 15 minutes for the EpiOFF CXL treatment and 20 minutes for the EpiON CXL treatment. Estimates of riboflavin concentration into the cornea will be monitored by the C4V CHROMO4VIS™ system during the dosing phase of treatment. Once the dosing phase is completed, the C4V CHROMO4VIS™ system provides the Operator the access to the UV-A irradiation of the cornea with 5.4 J/cm2 total energy dose and 7.00 mm light beam diameter in all participants. Estimates of treatment efficacy by calculation of theranostic score will be performed by the C4V CHROMO4VIS™ system during UV-A irradiation.
Primary Outcome Measure Information:
Title
Validation of the theranostic score
Description
The aim of this study is to validate the Theranostic Imaging Biomarker for theranostic-guided corneal corneal cross-linking (CXL) in patients with keratoconus
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Corneal topography
Description
Change of Maximum Simulated Keratometry
Time Frame
12 months
Title
Endothelial Cell Density
Description
Change of Endothelial Cell Density
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
Manifest Refraction
Description
Change of Manifest Sphrical Equivalent Refraction
Time Frame
12 months
Title
Corrected Distance Visual Acuity
Description
Change of Corrected Distance Visual Acuity
Time Frame
12 months
Title
Uncorrected Distance Visual Acuity
Description
Change of Uncorrected Distance Visual Acuity
Time Frame
12 months
Title
Validation of the theranostic score
Description
Assess the Theranostic Imaging Biomarker for theranostic-guided corneal corneal cross-linking (CXL) in patients with keratoconus
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: criteria for inclusion in the clinical trial are those currently referred to as the golden standard for the treatment of corneal cross-linking. The criterion to determine progression of keratoconus is based on providing at least one of the following evidences: at least two Placido disk corneal topography measurements showing at least +1.00 D steepening of the Kmax value in the last year or longer interval period. at least two manifest refraction measurements showing at least -0.50 D change in spherical equivalent refraction in the last year or longer interval period. at least two central corneal thickness (CCT) measurements showing at least -10 µm change in in the last year or longer interval period. Exclusion Criteria: Anterior corneal curvature steeper than 63 D; Corneal thickness thinner than 400 µm; Corneal scarring; Descemetocele; History of herpetic keratitis; Concomitant eye diseases; Inflammatory eye diseases; Glaucoma; Cataract; Nistagmus; Pregnancy; Breast feeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vincenzo Scorcia, MD
Organizational Affiliation
Azienda Ospedaliera Universitaria Mater Domini - Università Magna Graecia di Catanzaro
Official's Role
Principal Investigator
Facility Information:
Facility Name
Azienda Ospedaliera Universitaria Mater Domini - Università Magna Graecia di Catanzaro
City
Catanzaro
ZIP/Postal Code
88100
Country
Italy
Facility Name
Azienda Ospedaliera Universitaria Careggi, Università di Firenze
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Facility Name
Azienda Ospedaliera Universitaria Policlinico G. Martino, Università di Messina
City
Messina
ZIP/Postal Code
98124
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29451741
Citation
Lombardo G, Villari V, Micali NL, Leone N, Labate C, De Santo MP, Lombardo M. Non-invasive optical method for real-time assessment of intracorneal riboflavin concentration and efficacy of corneal cross-linking. J Biophotonics. 2018 Jul;11(7):e201800028. doi: 10.1002/jbio.201800028. Epub 2018 Apr 10.
Results Reference
background
PubMed Identifier
30360937
Citation
Lombardo M, Lombardo G. Noninvasive real-time assessment of riboflavin consumption in standard and accelerated corneal crosslinking. J Cataract Refract Surg. 2019 Jan;45(1):80-86. doi: 10.1016/j.jcrs.2018.07.062. Epub 2018 Oct 22.
Results Reference
background
PubMed Identifier
31900647
Citation
Lombardo G, Serrao S, Lombardo M. Comparison between standard and transepithelial corneal crosslinking using a theranostic UV-A device. Graefes Arch Clin Exp Ophthalmol. 2020 Apr;258(4):829-834. doi: 10.1007/s00417-019-04595-6. Epub 2020 Jan 3.
Results Reference
background
PubMed Identifier
26868750
Citation
Lombardo G, Micali NL, Villari V, Serrao S, Lombardo M. All-Optical Method to Assess Stromal Concentration of Riboflavin in Conventional and Accelerated UV-A Irradiation of the Human Cornea. Invest Ophthalmol Vis Sci. 2016 Feb;57(2):476-83. doi: 10.1167/iovs.15-18651.
Results Reference
background
PubMed Identifier
25542349
Citation
Lombardo M, Pucci G, Barberi R, Lombardo G. Interaction of ultraviolet light with the cornea: clinical implications for corneal crosslinking. J Cataract Refract Surg. 2015 Feb;41(2):446-59. doi: 10.1016/j.jcrs.2014.12.013. Epub 2014 Dec 23.
Results Reference
background
PubMed Identifier
36059083
Citation
Lombardo G, Bernava GM, Serrao S, Lombardo M. Theranostic-guided corneal cross-linking: Preclinical evidence on a new treatment paradigm for keratoconus. J Biophotonics. 2022 Dec;15(12):e202200218. doi: 10.1002/jbio.202200218. Epub 2022 Sep 16.
Results Reference
background
PubMed Identifier
36587174
Citation
Roszkowska AM, Lombardo G, Mencucci R, Scorcia V, Giannaccare G, Vestri A, Alunni Fegatelli D, Bernava GM, Serrao S, Lombardo M. A randomized clinical trial assessing theranostic-guided corneal cross-linking for treating keratoconus: the ARGO protocol. Int Ophthalmol. 2023 Jul;43(7):2315-2328. doi: 10.1007/s10792-022-02628-4. Epub 2022 Dec 31.
Results Reference
background
Links:
URL
https://regensight.com/en/science-technology/
Description
Updates on clinical trial RSKC001

Learn more about this trial

Theranostic Guided Riboflavin/UV-A Corneal Cross-linking

We'll reach out to this number within 24 hrs